Takeover Battle: Novo Nordisk Wins Brave Court Victory in $10B Metsera Deal Amid FTC Probe
Novo Nordisk’s $10 billion takeover for Metsera has survived a Delaware court challenge from Pfizer but now faces federal scrutiny from the FTC.
Cardiometabolic
Obesity Drug Talks Reach Defining Moment as Lilly and Novo Near Trump Administration Pricing Deal
In a major policy moment, Lilly and Novo Nordisk are in active talks with U.S. officials to cap obesity drug prices, aligning political pressure with market strategy.
Lepu Medical Licenses Promising Triple-Agonist Platform to Denmark’s Sidera Bio in Global Metabolic Push
Lepu Medical expands its biotech footprint through a licensing deal with Sidera Bio for MWN105, a triple-agonist drug targeting obesity and metabolic disorders, combining equity, milestone, and royalty gains in a global partnership.
Cardiac MRI Matches SPECT Accuracy While Eliminating Radiation Risk
Cardiac MRI is proving its place as a powerful, radiation-free alternative to SPECT in diagnosing coronary artery disease.
Reimbursement Series: CMS and Europe Reimbursement Pathway Accelerates Innovation
In a transformative week for market access, the CMS and Europe reimbursement pathway expansion delivered several pivotal coverage and pricing decisions reshaping patient access across cardiovascular, hepatic, and oncology therapies. From CMS’s national determinations on breakthrough devices to European HTA approvals in rare disease and cancer, these developments underscore a growing transatlantic alignment between regulators … Read more
Regeneron Unlocks Game-Changing Multispecific Antibody Pact
Regeneron boosts its pipeline with multispecific platform for disease innovation.
Reimbursement Series: Anchors Affordable Breakthroughs – AIFA and TLV Expand European Coverage
Sweden expands reimbursement decisions driving biotech access and patient impact.
NICE accelerates breakthrough framework for complex liver diseases
NICE drives innovation, reshaping MASH evaluations with transformative guidance.
Novartis secures triumphant $12 billion takeover of Avidity
The billion-dollar acquisition advances Avidity’s RNA platform with momentum.
Novartis Inks $750M Flagship Pact for Cardio Innovation
Novartis makes a $750M flagship pact to address cardiovascular disease innovation.